The strategic agreements mark Pathos AI's expansion from oncology into neurological conditions, beginning with Alzheimer's disease treatments.

From the articleAI drug firm Pathos raises $237 million, pushing valuation to $3 billionAlso in AI drug development startup Pathos AI closes $237M investment - SiliconANGLE, Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development | Reuters